{"id":99002,"date":"2025-09-21T00:08:06","date_gmt":"2025-09-21T00:08:06","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/nvo-important-deadline-rosen-skilled-investor-counsel-encourages-novo-nordisk-a-s-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-september-30-deadline-in-securities-cla\/"},"modified":"2025-09-21T00:08:06","modified_gmt":"2025-09-21T00:08:06","slug":"nvo-important-deadline-rosen-skilled-investor-counsel-encourages-novo-nordisk-a-s-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-september-30-deadline-in-securities-cla","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/nvo-important-deadline-rosen-skilled-investor-counsel-encourages-novo-nordisk-a-s-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-september-30-deadline-in-securities-cla\/","title":{"rendered":"NVO IMPORTANT DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Novo Nordisk A\/S Investors with Losses in Excess of $100K to Secure Counsel Before Important September 30 Deadline in Securities Class Action – NVO"},"content":{"rendered":"
\n

NEW YORK, Sept. 20, 2025 (GLOBE NEWSWIRE) — <\/p>\n

WHY:<\/strong>\u00a0Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A\/S (NYSE: NVO) between May 7, 2025 and July 28, 2025, both dates inclusive (the \u201cClass Period\u201d), of the important September 30, 2025 lead plaintiff deadline<\/strong>.<\/p>\n

SO WHAT<\/strong>: If you purchased Novo Nordisk securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.<\/p>\n

WHAT TO DO NEXT: <\/strong>To join the Novo Nordisk class action, go to https:\/\/rosenlegal.com\/submit-form\/?case_id=34168<\/a> or call Phillip Kim, Esq. at 866-767-3653 or email case@rosenlegal.com<\/a> for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court\u00a0no later than September 30, 2025<\/strong>. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.<\/p>\n

WHY ROSEN LAW:<\/strong> We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. <\/strong>Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs\u2019 Bar. Many of the firm\u2019s attorneys have been recognized by Lawdragon and Super Lawyers.<\/p>\n

DETAILS OF THE CASE:<\/strong> According to the lawsuit, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and\/or concealing material adverse facts concerning the true state of Novo Nordisk\u2019s growth potential. Notably, Novo Nordisk\u2019s asserted potential to capitalize on the compounded market greatly understated the potential impact of the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood that such patients would switch to Novo Nordisk\u2019s branded alternatives. Further, defendants greatly overstated the potential GLP-1 market or otherwise, Novo\u2019s capability to penetrate said markets to achieve continued growth. When the true details entered the market, the lawsuit claims that investors suffered damages.<\/p>\n

To join the Novo Nordisk class action, go to https:\/\/rosenlegal.com\/submit-form\/?case_id=34168<\/a> or call Phillip Kim, Esq. at 866-767-3653 or email case@rosenlegal.com<\/a> for more information.<\/p>\n

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor\u2019s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.<\/p>\n

Follow us for updates on LinkedIn: https:\/\/www.linkedin.com\/company\/the-rosen-law-firm<\/a>, on Twitter: https:\/\/twitter.com\/rosen_firm<\/a> or on Facebook: https:\/\/www.facebook.com\/rosenlawfirm\/<\/a>.<\/p>\n

Attorney Advertising. Prior results do not guarantee a similar outcome.<\/p>\n

——————————-<\/p>\n

Contact Information:<\/p>\n

\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Laurence Rosen, Esq.
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Phillip Kim, Esq.
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0The Rosen Law Firm, P.A.
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0275 Madison Avenue, 40th Floor
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0New York, NY 10016
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Tel: (212) 686-1060
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Toll Free: (866) 767-3653
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Fax: (212) 202-3827
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0case@rosenlegal.com<\/a>
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0www.rosenlegal.com<\/a><\/p>\n

\n <\/div>\n